Development of recombinant human granulocyte colony-stimulating factor (nartograstim) production process in Escherichia coli compatible with industrial scale and with no antibiotics in the culture medium
- PMID: 33201277
- DOI: 10.1007/s00253-020-11014-y
Development of recombinant human granulocyte colony-stimulating factor (nartograstim) production process in Escherichia coli compatible with industrial scale and with no antibiotics in the culture medium
Abstract
The granulocyte colony-stimulating factor (G-CSF) is a hematopoietic cytokine that has important clinical applications for treating neutropenia. Nartograstim is a recombinant variant of human G-CSF. Nartograstim has been produced in Escherichia coli as inclusion bodies (IB) and presents higher stability and biological activity than the wild type of human G-CSF because of its mutations. We developed a production process of nartograstim in a 10-L bioreactor using auto-induction or chemically defined medium. After cell lysis, centrifugation, IB washing, and IB solubilization, the following three refolding methods were evaluated: diafiltration, dialysis, and direct dilution in two refolding buffers. Western blot and SDS-PAGE confirmed the identity of 18.8-kDa bands as nartograstim in both cultures. The auto-induction medium produced 1.17 g/L and chemically defined medium produced 0.95 g/L. The dilution method yielded the highest percentage of refolding (99%). After refolding, many contaminant proteins precipitated during pH adjustment to 5.2, increasing purity from 50 to 78%. After applying the supernatant to cation exchange chromatography (CEC), nartograstim recovery was low and the purity was 87%. However, when the refolding solution was applied to anion exchange chromatography followed by CEC, 91%-98% purity and 2.2% recovery were obtained. The purification process described in this work can be used to obtain nartograstim with high purity, structural integrity, and the expected biological activity. KEY POINTS: • Few papers report the final recovery of the purification process from inclusion bodies. • The process developed led to high purity and reasonable recovery compared to literature. • Nartograstim biological activity was demonstrated in mice using a neutropenia model.
Keywords: Bioreactor cultivation; G-CSF; Inclusion bodies; Purification; Recovery; Refolding.
Similar articles
-
Expression of recombinant human mutant granulocyte colony stimulating factor (Nartograstim) in Escherichia coli.World J Microbiol Biotechnol. 2012 Jul;28(7):2593-600. doi: 10.1007/s11274-012-1068-4. Epub 2012 May 1. World J Microbiol Biotechnol. 2012. PMID: 22806165
-
Expression and purification of recombinant human granulocyte colony-stimulating factor in fed-batch culture of Escherichia coli.Appl Biochem Biotechnol. 2014 Mar;172(5):2425-35. doi: 10.1007/s12010-013-0708-y. Epub 2014 Jan 5. Appl Biochem Biotechnol. 2014. PMID: 24390866
-
Improved Production and Characterization of Recombinant Human Granulocyte Colony Stimulating Factor from E. coli under Optimized Downstream Processes.Protein Expr Purif. 2015 Apr;108:62-72. doi: 10.1016/j.pep.2015.01.010. Epub 2015 Feb 4. Protein Expr Purif. 2015. PMID: 25659501
-
Bioprocessing of therapeutic proteins from the inclusion bodies of Escherichia coli.Adv Biochem Eng Biotechnol. 2003;85:43-93. doi: 10.1007/3-540-36466-8_3. Adv Biochem Eng Biotechnol. 2003. PMID: 12930093 Review.
-
Expression, Solubilization, Refolding and Final Purification of Recombinant Proteins as Expressed in the form of "Classical Inclusion Bodies" in E. coli.Protein Pept Lett. 2021;28(2):122-130. doi: 10.2174/0929866527999200729182831. Protein Pept Lett. 2021. PMID: 32729411 Review.
References
-
- Babaeipour V, Khanchezar S, Mofid MR, Abbas MPH (2015) Efficient process development of recombinant human granulocyte colony-stimulating factor (rh-GCSF) production in Escherichia coli. Iran Biomed J 19(2):102–110. https://doi.org/10.6091/ibj.1338.2015 - DOI - PubMed - PMC
-
- Babaeipour V, Mofid MR, Khanchezar S, Faraji F, Abolghasemi S (2017) Bench-scale overproduction and purification of recombinant GCSF in Escherichia coli fed-batch process. J Appl Pharm Sci 7(8):149–155. https://doi.org/10.7324/japs.2017.70821 - DOI
-
- Babior MB, Golde DW (2011) Production, distribution, and fate of neutrophils. In: Wiliams hematology chapter, vol 66, 6th edn. Mc Graw Hill Editors, New York, pp 753–784
-
- Campani G, dos Santos MP, da Silva GG, Horta ACL, Badino AC, Giordano RC, Gonçalves VM, Zangirolami TC (2016) Recombinant protein production by engineered Escherichia coli in a pressurized airlift bioreactor: a techno-economic analysis. Chem Eng Process 103:63–69. https://doi.org/10.1016/j.cep.2015.10.020 - DOI
-
- Cardoso VM, Campani G, dos Santos MP, da Silva GG, Pires MC, Gonçalves VM, Giordano RC, Sargo CR, Horta ACL, Zangirolami TC (2020) Cost analysis based on bioreactor cultivation conditions: production of a soluble recombinant protein using Escherichia coli BL21(DE3). Biotechnol Rep 26:e00441. https://doi.org/10.1016/j.btre.2020.e00441 - DOI
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical